Toggle Main Menu Toggle Search

Open Access padlockePrints

Gene Therapy for Primary Immunodeficiencies: Current Status and Future Prospects

Lookup NU author(s): Professor Andrew GenneryORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Gene therapy using autologous haematopoietic stem cells offers a valuable treatment option for patients with primary immunodeficiencies who do not have access to an HLA-matched donor, although such treatments have not been without their problems. This review details gene therapy trials for X-linked and adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS) and chronic granulomatous disease (CGD). X-linked SCID was chosen for gene therapy because of previous 'natural' genetic correction through a reversion event in a single lymphoid precursor, demonstrating limited thymopoiesis and restricted T-lymphocyte receptor repertoire, showing selective advantage of progenitors possessing the wild-type gene. In early studies, patients were treated with long terminal repeats-intact gamma-retroviral vectors, without additional chemotherapy. Early results demonstrated gene-transduced cells, sustained thymopoiesis, and a diverse T-lymphocyte repertoire with normal function. Serious adverse effects were subsequently reported in 5 of 20 patients, with T-lymphocyte leukaemia developing, secondary to the viral vector integrating adjacent to a known oncogene. New trials using self-inactivating gamma-retroviral vectors are progressing. Trials for ADA-SCID using gamma-retroviral vectors have been successful, with no similar serious adverse effects reported; trials using lentiviral vectors are in progress. Patients with WAS and CGD treated with early gamma-retroviral vectors have developed similar lymphoproliferative adverse effects to those seen in X-SCID-current trials are using new-generation vectors. Targeted gene insertion using homologous recombination of corrected gene sequences by cellular DNA repair pathways following targeted DNA breakage will improve efficacy and safety of gene therapy. A number of new techniques are discussed.

Publication metadata

Author(s): Qasim W, Gennery AR

Publication type: Article

Publication status: Published

Journal: Drugs

Year: 2014

Volume: 74

Issue: 9

Pages: 963-969

Print publication date: 01/06/2014

Online publication date: 22/05/2014

ISSN (print): 0012-6667

ISSN (electronic): 1179-1950

Publisher: Springer


DOI: 10.1007/s40265-014-0223-7


Altmetrics provided by Altmetric